Introduction
Atherosclerosis is a chronic disease advancing over time by accumulation of atheromatous lesions within the intimal layer of the vessel wall in response to systemic risk factors and the local haemodynamic environment [1] . Medical interventions, including lipidlowering drugs and antihypertensive medications, have effectively reduced coronary atherosclerotic events [2] [3] [4] . However, understanding the change in the natural history of coronary atherosclerosis in response to these interventions has not been possible until recently. The advent of invasive imaging modalities allows us to quantify and morphologically characterise coronary atherosclerosis in vivo [5] . The effect of lipid-lowering therapies on coronary atherosclerosis has been an important focus during recent years and CARDIOVASCULAR MEDICINE -KARDIOVASKULÄRE MEDIZIN -MÉDECINE CARDIOVASCULAIRE 2017;20 (10) :236-240 the modest regression in atheroma burden when highlipid lowering agents are administered represents an important advance in cardiovascular medicine [6] . The present review summarises the accumulated data on the effect of lipid-lowering therapies on coronary atherosclerosis.
In vivo assessment of coronary atherosclerosis
The three intravascular imaging modalities most frequently used for the assessment and quantification of coronary atherosclerosis are greyscale intravascular ultrasound (IVUS), optical coherence tomography and near-infrared spectroscopy [5] . However, to date, no single invasive imaging modality is able to assess the full scope of coronary atherosclerosis. The gold standard for assessing the effect of lipid-lowering therapy on coronary atherosclerosis is IVUS, as it is the only imaging modality that accurately delineates the vessel contours in the presence of large necrotic cores or calcifications and thereby allows an accurate quantification of the atheroma burden. For the purpose of the present review, we therefore only summarised findings obtained with IVUS. The variability of core laboratorybased tracing of the outer vessel wall and lumen with IVUS (i.e., the measurements required for atheroma quantification) is negligibly low. For example, in the REVERSAL study [7] , intra-observer and inter-observer variability was low for vessel area (-0. 16 
Quantification of coronary atheroma volume with IVUS
IVUS is based on acoustic sound wave backscattering.
The amplitude of the reflected ultrasound wave is used 
Effect of statin therapy on coronary atherosclerosis
In the last decade, serial IVUS studies assessed the progression of coronary atherosclerosis in response to statins. The REVERSAL study [7] 
Effect of ezetimibe on coronary atherosclerosis
The PRECISE IVUS study [10] 
Effect of PCSK9 inhibition as addition to statins in coronary atherosclerosis
The use of statins has successfully decreased the risk of cardiovascular events and its effect on coronary atheroma has been summarised above. However, despite successful LDL-C reduction with statin therapy, there still exists an unmet need for an additional/alternative LDL-C lowering therapy for further risk reduction.
Examples include patients with familial hyper- were independent predictors of plaque regression in both ASTEROID and SATURN [15] . This linear relation between on-treatment LDL-C levels and change in atheroma volume was also confirmed in studies investigating non-statin treatment regimens such as the PRECISE IVUS study (ezetimibe) [7] and the GLAGOV study (evolocumab s.c.) [13] .
Factors associated with coronary plaque regression or progression
Notwithstanding the clear mechanistic role of LDL-C in atherogenesis and the robust association with serial plaque imaging investigations, a notable proportion of patients who achieved very low LDL-C levels failed to show coronary plaque regression. Atheroma continued to progress in 34% of patients in the SATURN trial and in a strikingly similar 36% of patients in ASTEROID, despite low on-treatment LDL-C levels and overall atheroma regression [8, 9] . In a pooled analysis of seven serial IVUS trials examining the vascular effects of statins and non-statin regimens, disease progression was observed in 20% of patients with LDL-C <70 mg/dl [14] . Increasing atheroma burden despite LDL-C levels below guideline-recommended thresholds was associ- The strongest multivariable predictor of PAV regression in SATURN was increased baseline PAV [9] , suggesting that plaque regression under intensive statin therapy is more successful in patients carrying a high coronary atheroma burden.
ACS patients show a more intense reduction in coronary atheroma burden as compared to stable CAD patients, a finding that is probably related to a higher plaque burden at baseline [6] . For example, in the PRE-CISE IVUS study [10] , PAV reduction after 12 months of atorvastatin + ezetimibe therapy reached 2.3% in ACS patients and 1.2% in stable CAD patients. 
Association between plaque regression and clinical outcomes
The clinically relevant question is whether a condition of plaque stabilisation or regression as defined by serial IVUS translates into improved clinical outcomes.
Plaque burden at baseline
Plaque burden obtained at a single point in time correlates with established clinical risk factors and may predict subsequent clinical events [17] . In PROSPECT [18] , high plaque burden (>70%) at the index procedure was associated with major adverse cardiovascular events over a 3-year follow-up; however, clinical event rates
were low overall, and the impact of the change of plaque burden on clinical outcomes could not be assessed because serial intravascular imaging was not available. The low specificity (9.6%) of increased plaque burden as a predictor of major adverse cardiac and cerebrovascular events (MACCE) is also noteworthy, as it limits the clinical implications for routine patient evaluation and decision making. The association between increased plaque burden and future events was also consistently demonstrated in the VIVA study [19] and in noninvasive imaging studies using multidetector computed tomography [20] . The PREDICTION study [21] , a natural history study that was not limited to anatomic, but also assessed local haemodynamic plaque characteristics, corroborated the predictive impact of increased plaque burden at baseline. In addition, this study demonstrated the incremental value of low shear stress for identification of lesions that subsequently required percutaneous coronary intervention (PCI). The baseline percent atheroma volume has also been linked to subsequent clinical events. In the SAT-URN study [9] , each standard deviation increase of baseline PAV was correlated with a 28% increase in major adverse cardiovascular events.
Clinical implications of serial changes of coronary plaque burden
Our understanding of the clinical implications of serial changes of plaque burden is based mostly on indirect evidence and on post hoc analyses. Von Birgelen et al. [14] reported in an observational study that plaque progression detected with IVUS was associated with more frequent adverse clinical events. In a pooled analysis of six serial IVUS studies, Nicholls et al. [22] found that PAV progression was an independent predictor of major adverse cardiovascular events over a mean follow-up of 21 months. The majority of events were repeat revascularisation procedures, and an impact of plaque progression on mortality was not re- 
